Background Survival from cystic fi-
The prognosis for patients with cystic fibrosis has improved substantially over the past four decades.'2 The improved survival has been attributed to several factors, including earlier diagnosis,2 improved management of meconium ileus,' better dietary management and pancreatic enzyme supplementation,2 4 routine physiotherapy,5 the development of potent antipseudomonal antibiotics,6 and the emergence of specialist treatment centres.27 The relative importance ofthese treatments remains uncertain,2 though most patients with cystic fibrosis now receive extensive medical and paramedical support, often with repeated admissions to hospital.238 As the cystic fibrosis population expands medical facilities will have to increase to cope with their requirements. To provide estimates of the likely extent of the increase in numbers of patients with cystic fibrosis we have used mortality data for England and Wales to predict the likely trend in survival over the next decade, and to produce estimates of the size and age distribution of the cystic fibrosis population.
Another important aspect of the management of cystic fibrosis is the counselling of parents of affected children at the time of diagnosis.9 The recent development of accurate prenatal diagnostic methods for cystic fibrosis""'2 is also likely to lead to a rapid increase in the numbers of parents seeking advice on whether to abort an affected fetus." 13 In both of these circumstances accurate data on survival prospects are required, and are currently not available. We have therefore used our data predications to estimate the likely life expectancy of children born with cystic fibrosis in England and Wales up to the present day.
Methods
Mortality data for cystic fibrosis in England and Wales from 1959 to 1986 were obtained from the Office of Population, Censuses, and Surveys. '4 The number of children born with cystic fibrosis each year was estimated from the total recorded live births,'5 16 on the assumption that one infant in 2500 is homozygous for cystic fibrosis.'7 We combined these estimates to produce life tables and annual mortality rates for cystic fibrosis for each year of birth cohort from 1959 to 1986, using the Statistical Package for the Social Sciences (SPSS-X).'8 Predictions of survival up to the year 2000 were derived by logistic and least squares regression, the generalised linear interactive modelling package (GLIM) being used. '9 In all birth cohorts mortality was much higher in the first year of life than in subsequent years, though first year mortality improved substantially during the study period ( fig 1A) . Mortality after the first year was relatively constant within birth cohorts. First year mortality was therefore analysed and predicted separately from subsequent mortality. A logistic regression equation,y = ax + b, was fitted to the proportion of affected children dying from cystic fibrosis in the first year of life for each birth cohort from 1959 to 1986, where y represents the logit of the proportion of deaths in any year, x the year, a the logistic gradient (the increase in the logit for each year), and b the logistic intercept ( fig 3) . A This study was conducted primarily to modest increase of only 133 children with estimate the numbers of patients with cystic cystic fibrosis (4%) is predicted for England fibrosis by the end of the next decade, and to and Wales from 1990 to 2000, whereas the provide estimates of life expectancy for chilincrease in the adult population will be of the dren with cystic fibrosis born now. We have order of 36% (676 individuals). The greatest used death certificate data from the Office of increase in the adult population will occur in Population Censuses and Surveys as this is the those over 25 years (from 517 to 1280). most complete source of national mortality data Estimated median survival for cohorts born available. Coding for cystic fibrosis deaths has changed on two occasions since 1959. For the The improvement in survival is likely to continue over the next decade with improved medical care and increased availability ofheartlung transplantation. Our predictions of median survival for future cohorts were very sensitive to the model used, so we have reported our estimates only up to the present birth cohort. As these predictions are based on cumulative estimates from multiple birth cohort survival predictions they contain an element of error that is difficult to estimate. As there is so far no evidence that survival is plateauing, our current estimates are likely to be reasonably accurate. The relatively favourable outlook (compared with that of 30 years ago) for a child born in 1990 with cystic fibrosis should allow reasonably optimistic advice to be given to parents. The current median age of death in England and Wales is of the order of 20 years,'4 and advice based on these figures will be unduly pessimistic. The continuing improvement in prognosis also raises questions about the acceptability of population and prenatal screening,23 as many couples are likely to question the morality of an abortion when a child born with cystic fibrosis may have a median survival of the order of 40 years." It may also be difficult to justify expensive population screening for a disease with such a prognosis,11 given that many adults with cystic fibrosis enjoy a good quality of life and contribute to society economically and socially. 24 We believe that our figures provide grounds for some optimism for those concerned with the care of patients with cystic fibrosis and with counselling parents of children born recently with cystic fibrosis, parents ofa fetus likely to be affected by cystic fibrosis, and young patients with the disease. This atlas contains 56 reports of rarities, largely from the National Research Institute ofMother and Child in Rabka, Poland. I envy them their 640 beds for paediatric respiratory medicine and their wealth ofclinical material. Clearly the investigative facilities as revealed here are not fully up to modem standards. The computed tomograms are scanty and there are no nuclear magnetic resonance images. In consequence, bronchography is performed far more often than in Western Europe. The planning of each report is good, and there are some interesting cases; there is a presentation, imaging studies, and pathological material. The illustrations are copious but tend to be poorly reproduced; and it is not easy to get used to reversed radiographs (black bones, white air). Latin is overused ("compressio trachea post destropositionem arteriae pulmonalis sinistrae" does not often trip off the tongue in my hospital). Unfortunately, no attempt is made to use these fascinomas to illustrate general principles. There is no mention of paediatric HIV. The use of fibreoptic bronchoscopy and transbronchial biopsy is not explored. The references are grouped alphabetically at the end of the book, rather than being attached to the case report to which they refer, and some are incomplete and outdated. But this is a very impressive attempt at producing a text of fascinating problems with limited funding and facilities. The authors are to be congratulated on their enterprise. This is mainly a book for the medical historian, possibly a book to skim but not one to buy for yourself. 
